Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign

Amber Tong

Paul Schloesser

Associate Editor

For the past year or so, Covid-19 has dominated the narrative around AstraZeneca. And for good reason: The pharma giant has shipped 2.6 billion doses …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign

Amber Tong

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Pas­cal So­ri­ot: As­traZeneca 'on track' to hit big $40B goal, cap­ping years-long turn­around cam­paign

Associate Editor

Sign up to read this article for free.

more like this

Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign